Explore the words cloud of the IMMUNISA project. It provides you a very rough idea of what is the project "IMMUNISA" about.
The following table provides information about the project.
KATHOLIEKE UNIVERSITEIT LEUVEN
|Coordinator Country||Belgium [BE]|
|Total cost||5˙999˙999 €|
|EC max contribution||5˙999˙999 € (100%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-12-01 to 2022-11-30|
Take a look of project's partnership.
|1||KATHOLIEKE UNIVERSITEIT LEUVEN||BE (LEUVEN)||coordinator||496˙875.00|
|2||INC RESEARCH UK LTD||UK (CAMBERLEY)||participant||3˙368˙802.00|
|3||ISA THERAPEUTICS BV||NL (LEIDEN)||participant||1˙653˙009.00|
|4||GRANZER HEINZ ULRICH||DE (MUNCHEN)||participant||267˙187.00|
|5||TTOPSTART BV||NL (UTRECHT)||participant||183˙875.00|
|6||EUROPEAN CANCER PATIENT COALITION||BE (BRUXELLES)||participant||30˙250.00|
Cervical cancer (CxCa) is caused by high risk types of the human papillomavirus (a.o. HPV16). Prophylactic HPV vaccination is not the standard of care in all European countries, and where approved it is not sufficiently adopted. Once infected, these vaccines no longer prevent premalignant lesions and CxCa, which can only be treated with surgery or radio-chemotherapy. However, this is not effective in recurrent/advanced CxCa. In underdeveloped countries, CxCa is often detected when it is too late for curative treatment. With an estimated global incidence of 500.000 new cases of CxCa and 274.000 deaths per year, the need for an effective therapy is extremely high. Targeted immunotherapy is an effective approach to induce a tumour-directed immune response. Previously, members of the IMMUNISA consortium have formulated ISA101, a cancer vaccine consisting of overlapping synthetic long peptides covering all epitopes of the HPV16 oncogenic proteins. ISA101 has shown promising Phase 1 clinical trial results in patients with advanced CxCa where it works synergistically with chemotherapy. IMMUNISA now proposes the multi-centre randomised Phase 2 CervISA-2 trial; a careful assessment of the efficacy of the proprietary ISA101b therapeutic vaccine in combination with chemotherapy for the treatment of CxCa, measured by a prolonged progression free survival. A multidisciplinary collaboration between leading clinical EU sites specialised in CxCa, a partner providing strategic and operational regulatory service and a cutting-edge biotech SME will enable the optimal implementation of the CervISA-2 trial, exploitation activities and overall project dissemination. This is pivotal to catapult further development of ISA101b as a commercial vaccine and push it towards clinical implementation as fast as possible. For ISA101b, IMMUNISA will provide, 1) clinical data on the efficacy, 2) a solid exploitation strategy and 3) the regulatory framework for efficient translation to clinical use.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUNISA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IMMUNISA" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in OsteoarthritisRead More
ENDOSCAPE, a clinically applicable non-viral gene delivery technologyRead More